Newsroom

CHICAGO--(BUSINESS WIRE)--EyeMD EMR Healthcare Systems, Inc., (“EyeMD EMR” or “the Company”), a leading provider of healthcare technology software solutions purpose-built for ophthalmologists and eye care specialists, announced a significant majority growth investment from Performant Capital, a Chicago-based private equity firm focused on partnering with and scaling software and technology-enabled businesses. Performant’s investment marks the next step in EyeMD EMR’s growth journey, supporting...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced an updated 18-month DOR of 80.6% (95% CI: 74.0, 85.7), by Kaplan-Meier estimate, from the Phase 3 ENVISION trial of UGN-102 (mitomycin) for intravesical solution, an investigational treatment for recurrent LG-IR-NMIBC. These data were featured today in an Oral Presentation Session (Abs...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The trial met its primary endpoint of event-free survival (EFS) by investigator assessment, demonstrating a cli...

LOS ANGELES--(BUSINESS WIRE)--NSSC Investors Have Opportunity to Lead Napco Security Technologies, Inc. Securities Fraud Lawsuit with the Schall Law Firm...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced encouraging safety data from the Phase 1 dose-escalation study for UGN-301 (zalifrelimab) intravesical solution, an investigational drug in development for the treatment of recurrent non-muscle invasive bladder cancer (NMIBC). "The early safety profile and clinical activity results fro...

HUNT VALLEY, Md.--(BUSINESS WIRE)--Diamond Comic Distributors (“Diamond” or “the Company”), today announced that it will no longer be moving forward in the transaction process with Alliance Entertainment. “Diamond Comic Distributors has pivoted to alternative, exceptionally well-known purchasers who are excited to partner with us. These companies have strong balance sheets and, importantly, unmatched presence and experience in our core industries,” said Diamond Chief Restructuring Officer Rober...

SAN FRANCISCO--(BUSINESS WIRE)--Attendees will learn how to identify cryptographic blind spots, high-risk certificates, and transition to quantum-safe alternatives....

ST. LOUIS--(BUSINESS WIRE)--EyeCare Partners will bring a strong lineup of clinical research and innovation to the upcoming annual ASCRS meeting....

GARDEN GROVE, Calif.--(BUSINESS WIRE)--US Metro Bancorp (OTCQX: USMT): US Metro Bancorp (“Bancorp”) is a bank holding company, with a single subsidiary, US Metro Bank (“Bank”). On a consolidated basis, Bancorp earned $2.6 million in the first quarter of 2025, compared to $1.7 million in the fourth quarter of 2024. For the three months ending March 31, 2025, the consolidated Bancorp earned $2.6 million compared to $1.5 million for the three months ending March 31, 2024. On a year-to-date basis,...

ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti”) (NYSE American: MRT), Türkiye’s leading mobility super app, will announce its full year 2024 financial and operational results before the U.S. markets open on Tuesday, April 29, 2025. Conference Call and Webcast Details Marti’s management will host an analyst and investor conference call and live webcast to discuss its financial results at 3:30 p.m. Istanbul / 1:30 p.m. London / 8:30 a.m. New York time on Tuesday, April 29, 2025. Liv...